Table 4 Absolute difference in adjusted cumulative incidence of diabetes (95% CI)
6 months | 12 months | 18 months | 24 months | |
|---|---|---|---|---|
DOACs vs Warfarin (ref.) | ||||
Apixaban vs Warfarin | − 0.79 (− 1.55 to 0.06) | − 1.21 (− 2.44 to 0.09) | − 1.66 (− 3.34 to 0.13) | − 2.06 (-4.08 to 0.16) |
Dabigatran vs Warfarin | − 1.17 (− 1.86 to − 0.41) | − 1.80 (− 2.86 to − 0.65) | − 2.47 (− 3.93 to − 0.92) | − 3.06 (− 4.79 to − 1.15) |
Rivaroxaban vs Warfarin | − 0.69 (− 1.42 to 0.09) | − 1.06 (− 2.14 to 0.13) | − 1.46 (− 2.93 to 0.19) | − 1.80 (− 3.62 to 0.23) |
Apixaban/ Rivaroxaban vs Warfarin | − 0.74 (− 1.39 to − 0.05) | − 1.14 (− 2.10 to − 0.08) | − 1.56 (− 2.83 to − 0.11) | − 1.93 (− 3.62 to − 0.14) |
DOACs vs DOACs (ref.) | ||||
Apixaban vs Dabigatran | 0.38 (− 0.38 to 1.13) | 0.59 (− 0.59 to 1.69) | 0.81 (− 0.79 to 2.34) | 1.00 (− 0.97 to 2.86) |
Rivaroxaban vs Dabigatran | 0.48 (− 0.20 to 1.11) | 0.74 (− 0.31 to 1.73) | 1.01 (− 0.43 to 2.31) | 1.26 (− 0.52 to 2.86) |
Rivaroxaban vs Apixaban | 0.10 (− 0.73 to 0.85) | 0.15 (− 1.07 to 1.34) | 0.21 (− 1.49 to 1.85) | 0.26 (− 1.81 to 2.30) |
Apixaban/ Rivaroxaban vs Dabigatran | 0.43 (− 0.14 to 0.93) | 0.66 (− 0.22 to 1.42) | 0.91 (− 0.31 to 2.00) | 1.13 (− 0.38 to 2.47) |